101 results

• Medtronic Dialysis Catheter Recall Issued Over Risk of Leaks

  July 12, 2022

  Russell Maas

  Medtronic is recalling more than a million dialysis catheters due to a risk of leaking which could lead to blood clots, strokes and heart attacks.

• Regular Aspirin Use Only Provides Slight Protection From Heart Disease, USPSTF Recommendations State

  May 3, 2022

  Martha Garcia

  A task force of U.S. medical experts says regular aspirin use does more harm than good for most patients, despite its protective measures against heart disease.

• Xeljanz Stroke Lawsuit Filed Against Pfizer for Gross Negligence in Failing to Warn About Drug Risks

  April 6, 2022

  Irvin Jackson

  A Xeljanz stroke lawsuit claims Pfizer failed to adequately warn about the drug's heart risks.

• Blood Thinner Extended Use Study Finds Little Difference in Warfarin, Xarelto, Eliquis Bleeding Rates

  March 18, 2022

  Irvin Jackson

  A new study finds little difference in major bleeding events between the newer blood thinners Xarelto and Eliquis and the older blood thinner warfarin they were supposed to replace.

• FDA Launches Investigation Into Potentially Toxic Nanoparticles Used In Blood Products

  March 7, 2022

  Martha Garcia

  The FDA has launched a new research program to investigate the potential health side effects of nanoparticles used in blood products.

• Makers of Oluminant Withdraw Lupus Treatment Approval Request in Face of JAK-Inhibitor Health Risks

  January 31, 2022

  Irvin Jackson

  A request for approval for Olumiant to treat lupus has been withdrawn, and the manufacturers expect the FDA to reject an atopic dermatitis approval request in the face of growing concerns over the side effects of similar arthritis drugs like Xeljanz.

• Rinvoq Approved As Atopic Dermatitis Treatment Despite Heart, Cancer Risks

  January 19, 2022

  Irvin Jackson

  The FDA has approved Rinvoq for the treatment of atopic dermatitis despite cancer and heart problem fears.

• Despite Side Effects of Xeljanz and Rinvoq, FDA Still Approves New Indications After Updated Warnings

  December 16, 2021

  Irvin Jackson

  The FDA has granted new approvals for rheumatoid arthritis drugs Xeljanz and Rinvoq despite concerns over heart, cancer and blood clot side effects.

• Rinvoq Warning Label Updated to Add Cancer and Heart Risks Seen With Xeljanz Side Effects

  December 6, 2021

  Irvin Jackson

  Rinvoq will now carry label warnings on cancer and heart risks which were first discovered through a study of Xeljanz side effects.

• Eli Lilly-Funded Study Claims Side Effects of Olumiant Do Not Warrant Same Adverse Label Warnings as Xeljanz

  November 16, 2021

  Irvin Jackson

  A new study announced by Eli Lilly appears to suggest Olumiant, a rheumatoid arthritis drug, does not need the same label warnings for heart problems as Xeljanz, it's competitor.